Clinical Trials Browser

Phase NA × Recurrence × pembrolizumab × Clear all

NCT05047094 2025-12-02

A Safety and Efficacy Study for Combinational Treatment of DaRT and Check Point Inhibitor for Recurrent Unresectable or mHNSCC

Phase NA Recruiting

DermatologicHead & Neck

Squamous Cell Carcinoma of Head and Neck, Carcinoma, Squamous Cell, Recurrence, Skin Neoplasms